Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.810
-0.020 (-1.09%)
Apr 20, 2026, 2:02 PM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $308.46 million as of April 20, 2026. Its market cap has increased by 57.21% in one year.
Market Cap
308.46M
Enterprise Value
132.26M
1-Year Change
57.21%
Ranking
Category
Stock Price
$1.81
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $308.46M, an increase of 207.06%. That is a compound annual growth rate of 23.49%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 17, 2026 | 311.87M | 11.22% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| NervGen Pharma | 329.39M |
| Zentalis Pharmaceuticals | 329.12M |
| Cellectis | 324.09M |
| LENZ Therapeutics | 319.19M |
| Abeona Therapeutics | 313.77M |
| NovaBridge Biosciences | 312.25M |
| Foghorn Therapeutics | 310.52M |
| Artiva Biotherapeutics | 310.19M |